Quantcast
Last updated on April 16, 2014 at 13:58 EDT

Latest Clostridium Stories

2011-05-09 12:00:00

CHICAGO, May 9, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the presentation of two abstracts at the 2011 Digestive Disease Week (DDW) conference highlighting additional analyses of data from Phase 3 trials of DIFICID(TM) (fidaxomicin), an investigational product for the treatment of Clostridium difficile infection (CDI). (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) The first analysis aimed to identify risk factors associated with...

2011-04-28 07:00:00

SAN DIEGO, April 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that additional data from the DIFICID(TM) Phase 3 trials will be presented at the following medical meetings: Digestive Disease Week (DDW), McCormick Place, Chicago, IL May 7-10, 2011 Poster Presentation Information: Risk of Recurrence and Time to Recurrence Following Title: Treatment of Clostridium difficile Infection:...

2011-04-28 07:00:00

MARLBOROUGH, Mass., April 28, 2011 /PRNewswire/ -- Qteros, Inc., the developer of a unique and highly efficient Consolidated Bioprocessing (CBP) platform for the lowest-cost production of cellulosic ethanol, today announced its plans to present at various industry conferences throughout the month of May. Kevin A. Gray, Ph.D., Senior Vice President and Chief Scientific Officer for Qteros, will deliver an oral presentation at the 33rd Symposium on Biotechnology for Fuels and Chemicals being...

2011-04-14 07:11:00

GREENSBORO, N.C., April 14, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC, maker of XEOMIN® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign. With the help of patient advocates, "Make Your Mark" celebrates the inspirational stories of people living with blepharospasm or cervical dystonia (CD), also known as spasmodic torticollis, and aims to raise awareness of these often...

2011-04-12 08:00:00

FRANKFURT, Germany, April 12, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced that results from sub-group analyses of a prospective, repeated dose, double-blind study evaluating the long-term safety and efficacy of XEOMIN® (incobotulinumtoxinA), a botulinum toxin type A free from accessory (complexing) proteins, will be presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii, U.S. The data show that repeated injections...

2011-04-11 15:05:00

LYNBROOK, N.Y., April 11, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that it will receive a $2.5 million milestone payment as a result of the European launch and first commercial sale of XIAPEX (collagenase clostridium histolyticum ) in the United Kingdom, a major European market. Pfizer, Inc. (Pfizer), the EU licensee received approval from the European Medicines...

2011-04-11 06:00:00

MALVERN, Pa., April 11, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Company will receive a $30 million regulatory milestone payment from its EU partner, Pfizer Inc. (Pfizer), following the first sale of XIAPEX in a major EU market. XIAPEX is a new non-surgical treatment option for Dupuytren's contracture in adult patients with a palpable cord and is the first injectable treatment to be approved in the...

2011-04-11 06:00:00

SUNNYVALE, Calif., April 11, 2011 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its Xpert® C. difficile/Epi test. Cepheid's first Xpert C. difficile test has been available in the United States since July 2009. The test's unique combination of high sensitivity and rapid turnaround time has quickly established Xpert C. difficile as the molecular market leader. Building on the...

2011-04-08 13:00:00

Clostridium difficile can lead to diarrhea, colitis SILVER SPRING, Md., April 8, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today cleared a test called the Cepheid Xpert C. difficile/Epi assay that is designed to rapidly detect the toxin B gene associated with Clostridium difficile infection (CDI), a cause of diarrhea that can lead to colitis, other serious intestinal conditions and death in severe cases. (Logo:...

2011-04-05 07:00:00

SAN DIEGO, April 5, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that NASDAQ has halted trading of the Company's common stock this morning. The Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and Drug Administration (FDA) is scheduled to meet today to review and discuss Optimer's New Drug Application (NDA) for fidaxomicin for the treatment of Clostridium difficile infection. (Logo:...


Latest Clostridium Reference Libraries

0_d6572564d3305dc462f4641398789e11
2011-04-15 13:32:47

Clostridium botulinum is a gram-positive, rod-shaped bacterium that produces neurotoxins, known as botulinum neurotoxins types A-G, that cause the flaccid muscular paralysis seen in botulism. It is the main paralytic agent in botox and is commonly found in soil. It is also an obligate anaerobe, meaning oxygen is poisonous to the cells. Superoxide dismutase helps C. botulinum tolerate traces of oxygen. It was first recognized and isolated in 1895 by Emile van Ermengem. Subsequent outbreaks...

More Articles (1 articles) »